Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2022-12-20 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Pharmaxis Skin Scarring Study Fully Recruited 2 pages 172.2KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 21 December 2022 from Pharmaxis Ltd announcing the completion of recruitment for a clinical trial phase of a drug study. It discusses the study details, expected results timeline, and background on the company and its drug development pipeline. There are no financial statements, regulatory filings, or detailed financial data presented. The document is a public announcement about clinical trial progress and future expectations, not a financial report, earnings release, or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a corporate announcement related to clinical trial progress and company updates, best classified as a general Regulatory Filing (RNS) since it does not fit other specific categories.
2022-12-20 English
Change in substantial holding 3 pages 169.5KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 under the Corporations Act 2001, which is a notice of change of interests of a substantial holder. It details voting power changes, relevant interests, and shareholdings of BVF Partners L.P. and associated entities. This type of filing is a notification of changes in significant share ownership levels, typically required when crossing ownership thresholds. It is not a financial report, earnings release, or management report, but a major shareholding notification as per the definitions provided.
2022-12-13 English
Pharmaxis Appoints Dr Simon Green as Director 2 pages 112.0KB
Board/Management Information Classification · 100% confidence The document is a media release announcing the appointment of Dr. Simon Green as a new independent non-executive director to the Board of Pharmaxis Ltd. It focuses on biographical details, the director's experience, and the company's business overview. There is no financial data, no discussion of financial results, no regulatory filings, no voting results, no legal proceedings, and no mention of any report publication. The content clearly fits the category of announcements related to changes in the company's board of directors or senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (6630 characters) supports that it is a full announcement rather than a brief note or a report publication announcement.
2022-12-13 English
Initial Director's Interest Notice 2 pages 139.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the initial director's relevant interests in securities and contracts, with no securities held or contracts disclosed. This is a report of personal share transactions or interests by a company director. The document length is short and focused solely on director's interests, matching the definition of Director's Dealing filings. Therefore, the appropriate classification is DIRS (Director's Dealing).
2022-12-13 English
Application for quotation of securities - PXS 6 pages 27.9KB
Capital/Financing Update Classification · 95% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and the nature of the securities being quoted. This is a formal announcement related to changes in the company's capital structure, specifically the issuance and quotation of new shares resulting from option exercises. It is not a financial report, earnings release, or management discussion, but rather a capital/financing update regarding securities quotation. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support this classification with high confidence.
2022-12-11 English
PXS Drug Profiled American Society of Hematology Conference 3 pages 199.7KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 12 December 2022 from Pharmaxis Ltd, discussing clinical trial data and scientific posters presented at the American Society of Hematology conference. It focuses on interim clinical data from a phase 2 study and pre-clinical research, with no detailed financial data or comprehensive financial performance analysis. The document is a public announcement of scientific and clinical development progress rather than a formal financial report or regulatory filing. It does not contain financial statements, audit information, or management discussion of financial results. Therefore, it does not fit categories like Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or Regulatory Filings (RNS). It is a press/media release announcing clinical development updates and scientific presentations, which aligns best with a general regulatory announcement or miscellaneous filing. Given the absence of a more specific category, the best fit is Regulatory Filings (RNS).
2022-12-11 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.